Risk for Adverse Events Up With Low-Dose Methotrexate
TUESDAY, Feb. 18, 2020 -- Use of low-dose methotrexate (LD-MTX) is associated with increased risks for adverse events (AEs), including skin cancer, and gastrointestinal, pulmonary, infectious, and hematologic AEs, according to research published...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Gastroenterology | Hematology | Methotrexate | Pharmaceuticals | Skin | Skin Cancer